Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVINASDAQ:GALTNASDAQ:JMACNASDAQ:OCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.23+13.9%$0.96$0.62▼$7.50$22.70M0.661.81 million shs777,496 shsGALTGalectin Therapeutics$1.41-10.5%$1.45$0.73▼$3.41$88.77M0.62316,045 shs132,799 shsJMACMaxpro Capital Acquisition$5.81-4.6%$6.80$7.50▼$19.22$78.02M0.0174,040 shs951 shsOCXOncoCyte$2.83$3.18$1.92▼$4.75$80.94M0.9557,109 shs22,752 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+13.89%+42.69%+73.73%-35.94%+153.45%GALTGalectin Therapeutics-10.51%+8.08%+10.63%+7.25%-56.64%JMACMaxpro Capital Acquisition-4.60%-11.84%-3.17%-30.00%+1,343.48%OCXOncoCyte+0.07%-8.71%+2.91%+40.80%-0.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie2.6234 of 5 stars3.84.00.00.02.80.00.6GALTGalectin Therapeutics0.7082 of 5 stars3.00.00.00.00.01.70.0JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AOCXOncoCyte1.7311 of 5 stars3.32.00.00.02.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 3.50Strong Buy$3.00143.90% UpsideGALTGalectin Therapeutics 2.00Hold$11.00682.92% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/AOCXOncoCyte 2.67Moderate Buy$4.4256.07% UpsideCurrent Analyst Ratings BreakdownLatest BIVI, JMAC, OCX, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.254/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/28/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.003/25/2025OCXOncoCyteStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$4.00 ➝ $4.003/25/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.253/18/2025BIVIBioVieBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.54 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.01) per shareN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AOCXOncoCyte$1.88M43.03N/AN/A$2.48 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$9.76N/A∞N/AN/A-134.07%-93.44%5/13/2025 (Estimated)GALTGalectin Therapeutics-$41.07M-$0.76N/AN/AN/AN/AN/A-163.15%5/21/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AOCXOncoCyte-$27.78M-$4.40N/AN/AN/A-6,122.29%-269.32%-59.71%5/13/2025 (Estimated)Latest BIVI, JMAC, OCX, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025GALTGalectin Therapeutics-$0.20N/AN/AN/AN/AN/A5/13/2025Q3 2025BIVIBioVie-$0.32N/AN/AN/AN/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/A3/24/2025Q4 2024OCXOncoCyte-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million2/11/2025Q1 2025BIVIBioVieN/A-$0.46N/A-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A16.9416.94GALTGalectin TherapeuticsN/A1.131.13JMACMaxpro Capital AcquisitionN/AN/AN/AOCXOncoCyteN/A0.530.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%GALTGalectin Therapeutics11.68%JMACMaxpro Capital Acquisition73.18%OCXOncoCyte55.35%Insider OwnershipCompanyInsider OwnershipBIVIBioVie4.00%GALTGalectin Therapeutics50.10%JMACMaxpro Capital Acquisition19.27%OCXOncoCyte1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1018.45 million17.71 millionNo DataGALTGalectin Therapeutics963.18 million31.32 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableOCXOncoCyte12028.60 million17.18 millionNo DataBIVI, JMAC, OCX, and GALT HeadlinesRecent News About These CompaniesOncoCyte Co. (NASDAQ:OCX) Shares Acquired by Broadwood Capital Inc.May 8 at 6:22 AM | marketbeat.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7 at 4:10 PM | globenewswire.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7 at 4:08 PM | prismmediawire.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 5.11%May 7 at 2:19 AM | aaii.comBest Momentum Stocks to Buy for May 6thMay 6 at 11:00 AM | zacks.comNew Strong Buy Stocks for May 6thMay 6 at 8:45 AM | zacks.comOncoCyte (NASDAQ:OCX) Trading Down 3.1% - Here's What HappenedMay 2, 2025 | marketbeat.comOncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | finanznachrichten.deOncocyte study links blood test to kidney rejection markersApril 30, 2025 | investing.comOncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | globenewswire.comOncocyte’s Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | taiwannews.com.twOncocyte's Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | globenewswire.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 12.22%April 25, 2025 | aaii.comNew Strong Buy Stocks for April 24thApril 24, 2025 | zacks.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 6.85%April 16, 2025 | aaii.comOncoCyte (NASDAQ:OCX) Receives Buy Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comOncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?April 7, 2025 | zacks.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | prismmediawire.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comOncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIVI, JMAC, OCX, and GALT Company DescriptionsBioVie NASDAQ:BIVI$1.23 +0.15 (+13.89%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$1.23 0.00 (0.00%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Galectin Therapeutics NASDAQ:GALT$1.40 -0.17 (-10.51%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$1.38 -0.03 (-1.78%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Maxpro Capital Acquisition NASDAQ:JMAC$5.81 -0.28 (-4.60%) As of 05/7/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.OncoCyte NASDAQ:OCX$2.83 0.00 (0.00%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$2.84 +0.01 (+0.35%) As of 05/8/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Bloomin’ Brands Stock Drops on Weak Guidance and Demand Concerns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
